MajesTEC-1

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Arms / Cohorts

Experimental Part 1:Teclistamab Intravenously (IV)

Accepting patients

Experimental Part 1:Teclistamab Subcutaneously (SC)

Accepting patients

Experimental Part 2:Teclistamab Intravenously (IV)

Accepting patients

Experimental Part 2:Teclistamab Subcutaneously (SC)

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.